Cardiovascular

Educational resources

eLearning module index image

The importance of reducing cardiovascular risk in patients with type 2 diabetes

Promotional material from the Boehringer Ingelheim and Lilly Alliance

This eLearning module has been commissioned and funded by the Boehringer Ingelheim and Lilly Alliance and developed in partnership with Guidelines in Practice and Guidelines Learning. Products are discussed. This eLearning module is intended for healthcare professionals.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
PC-GB-105238  September 2021

NICE AF RTD - digital

NICE atrial fibrillation: diagnosis and management guideline (NG196) update—treatment considerations for direct-acting oral anticoagulants (DOACs)

Commissioned by Bayer Plc

Information intended for UK healthcare professionals only. This round-table discussion supplement has been commissioned and funded by Bayer plc and developed in partnership with Guidelines in Practice.
View Xarelto® (rivaroxaban) adverse event reporting and prescribing information
PP-XAR-GB-2369
Date of preparation: November 2021

Jardiance HF FDG_index image

Jardiance® (empagliflozin) film-coated tablets for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF)

Promotional material from the Boehringer Ingelheim and Lilly Alliance

This formulary decision guide was commissioned by the Boehringer Ingelheim and Lilly Alliance. 
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain and Northern Ireland.
PC-GB-105819 October 2021

Jardiance SMC guidance card index image

Empagliflozin (Jardiance®) 10mg film-coated tablets SMC2396

Promotional material from the Boehringer Ingelheim and Lilly Alliance

The production of this Guidelines  summary card has been commissioned by the Boehringer Ingelheim and Lilly Alliance.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain and Northern Ireland.
PC-GB-105815 October 2021

Trajenta animation updated index image

Prescribing a dipeptidyl peptidase-4 inhibitor in adults with type 2 diabetes and comorbidities

Commissioned by Boehringer Ingelheim Limited

This animation has been commissioned and funded by Boehringer Ingelheim Limited and developed in partnership with Guidelines in Practice.
View Trajenta (linagliptin) adverse event reporting and prescribing information for Great Britain or Northern Ireland
PC-GB-105090 Date of preparation: October 2021

Guidelines summaries

  • NICE heart valve disease guideline

    Thu, 09 Dec 2021 15:15:00 GMT

    Covering investigation and management of heart valve disease in adults

  • NICE CVD guideline

    Fri, 22 Oct 2021 00:00:00 GMT

    A concise summary of NICE's evidence-based clinical guideline on lipid modification for the prevention of cardiovascular disease

  • ABCD position on cardiovascular impact of glucose-lowering drugs

    Thu, 09 Sep 2021 09:04:00 GMT

    Key recommendations from the ABCD position statement on new glucose-lowering drugs concerning their cardiovascular impact on people with diabetes

  • COVID-19 rapid guideline on VITT

    Tue, 10 Aug 2021 14:19:00 GMT

    This Guidelines summary covers vaccine-induced immune thrombocytopenia and thrombosis, a syndrome that has been reported in rare cases after COVID-19 vaccination

  • NICE atrial fibrillation guideline

    Mon, 05 Jul 2021 09:59:00 GMT

    A clear summary of NICE’s guideline on atrial fibrillation management